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Coronary Vasodilatory Action 
After a Single Dose of Nicorandil 
HARYANTO SURYAPRANATA, MD, PATRICK W. SERRUYS, MD, 
PIM J. DE FEYTER, MD, PIETER D. VERDOUW, PhD, 
and PAUL G. HUGENHOLTZ, MD 
Coronary hemodynamics and vasodilatory effects on 
major epicardial arteries were investigated after a 
single dose of nicorandil in 22 patients undergoing 
cardiac catheterization for suspected coronary ar- 
tery disease. Nicorandil, 20 mg, was administered 
sublingually to 11 consecutive patients and 40 mg 
to 11 others. Systemic blood pressure decreased 
significantly without affecting the heart rate. Coro- 
nary sinus blood flow did not change significantly. 
As the mean aortic pressure decreased signtficantly 
by 13 % after 20 mg and 21% after 40 mg of nico- 
randil, the calculated coronary vascular resistance 
decreased but did not reach statistical significance. 
There was a decrease in myocardial oxygen con- 
sumption (-14% and -22%) respectively), and 
this was consistent with a significant decrease in 
the calculated pressure-rate product of 19 % and 
24 % , respectively. A total of 103 selected coronary 
segments, including 17 stenotic segments, were an- 
aiyzed quantitatively using a computer-assisted cor- 
onary angiography analysts system. After 20 or 40 
mg of nicorandil, a signiftcant increase of the mean 
diameter was observed in the proximal (+9% and 
+7%), midportion (-HO% and +ll%) and diil 
(i-15% and +13%) parts of the left anterior de- 
scending coronary artery. Correspondii values for 
the proximal (+ 13 % and HO%) and distal 
(-t-10% and +15%) segments of the circumflex 
artery were observed. An increase in the obstruc- 
tion diameter was also observed in all but 3 of the 
analyzed stenotic segments. The results demon- 
strate that nicorandil, in the route and doses used, 
causes a significant vasodilatation in the major epi- 
cardial coronary segments, includii most stenotlc 
segments, and decreases the myocardial oxygen 
demand with little effect on the resistance vessets. 
(Am J Cardioi 1988;81:292-297) 
N icorandil (N-(2-hydroxyethyl) nicotinamide nitrate 
(ester)] is a potent coronary vasodilator and when ad- 
ministered orally, is rapidly absorbed from the mucosa 
of oral cavity and gastrointestinal tract.lJ The pharma- 
cologic profile is partly similar to that of nitroglycerin.3 
Both induced similar dose-related changes in the he- 
modynamics and coronary circulation,4 but unlike ni- 
troglycerin, nicorandil developed only slight tolerance 
in vivo, and no tolerance in vitro.5 Previous experi- 
mental and clinical data have shown that nicorandil, 
in dose-dependent increments, decreased peripheral 
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resistance, decreased end-diastolic and end-systolic 
volumes and increased the coronary blood flow with 
little effects on myocardial oxygen consumption and 
atrioventricular conductionlJv4J-12 The effects of ni- 
corandil indicate a preload reduction equal to nitro- 
glycerin and an afterload reduction approaching that 
of dihydralazine. l3 In the nonischemic heart, nicoran- 
dil dose-dependently increases transmural left ven- 
tricular blood flow with the greatest increases occur- 
ring in the sub- and midepicardium.7-gJ4J5 It appears 
to act primarily by dilatation of the large coronary 
arteries with little effect on the myocardium.3~g*11J6 
We investigated the coronary hemodynamic effects 
and assessed, quantitatively, the vasodilatory effect on 
the epicardial vessels after a single dose of nicorandil. 
A computer-assisted coronary angiography analysis 
system was used to quantify changes in the coronary 
diameters. 
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Methods 
Patients: The study population consisted of 22 pa- 
tients (19 men and 3 women], undergoing cardiac cath- 
eterization for the investigation of suspected coronary 
artery disease. The mean age was 54 years [range 39 to 
68). All were in sinus rhythm, none had signs of cardi- 
ac failure and all gave informed consent to participate 
in the study. The effects of 2 different dosages of nico- 
randil were investigated; nicorandil 20 mg (group 1) 
was given sublingually to 11 consecutive patients and 
40 mg (group 2) to 11 others. Clinical and angiographic 
data are summarized in Table I. The groups were com- 
parable with respect to age, degree of coronary artery 
disease, resting ejection fraction and coronary sinus 
blood flow (unpaired Student t test]. 
Protocol: All medications were discontinued at 
least 24 hours before the study. Cardiac catheterization 
was performed with patients in the fasting state with- 
out premeditation. After a Webster thermodilution 
flow catheter was inserted into the coronary sinus, 
angiography of the right and left coronary artery was 
performed in standard views, including cranial and 
caudal angulations. The geometry of the x-ray gantry, 
and the kilovolts and milliamperes of the x-ray genera- 
tor were acquired and recorded on-line for each angi- 
ogram. Heart rate, aortic pressures, thermodilution 
coronary sinus blood flow and oxygen saturation ob- 
tained simultaneously from the aorta and coronary si- 
nus were measured in the resting state 15 minutes after 
coronary angiography. Nicorandil, 20 or 40 mg, was 
then administered sublingually and all measurements 
were repeated at 5, 10, 20 and 30 minutes. Left coro- 
nary angiography was repeated 30 minutes after the 
drug administration in all projections, corresponding 
to those used during control angiograms, in order to 
study the effect on the dimensions of the epicardial 
coronary arteries. All angiograms were obtained using 
the Judkins technique and recorded on Kodak 35-mm 
cinefilm at a rate of 25 frames/s. A nonionic contrast 
medium (iopamidol) was injected manually. 
Coronary sinus blood flow measurements and cal- 
culations: The on-line computer system assessed the 
coronary sinus blood flow using a constant infusion 
thermodilution technique. Arterial and coronary si- 
nus blood oxygen saturation were measured spectro- 
photometrically (Lex-O&ON, Lexington Instruments 
Corp.) and oxygen content calculated. Myocardial 
oxygen consumption was calculated as a product of 
coronary sinus blood flow and arterial-coronary sinus 
oxygen content difference. Coronary vascular resis- 
tance was derived from the ratio of the mean aortic 
pressure to coronary sinus blood flow. 
Quantitative coronary angiography: The quantita- 
tive analysis of selected coronary segments was car- 
ried out with the computer-assisted Coronary Angiog- 
raphy Analysis System (CAAS), which has been de- 
scribed in detail previously.17s1* To analyze a coronary 
arterial segment in a selected frame of 35-mm cine- 
film, an optically magnified portion of the image en- 
compassing that segment is converted into video for- 
mat by means of a tine-video converter. The contours 
TABLE I Baseline Data of Patients Receiving 20 mg of Nicorandil 
(Patients 1 to 11) and 40 mg (Patients 12 to 22) 
Coronary Artery Disease 
Age (yr), EF 
R Sex NYHA PMI LM LAD LC Right (%) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
45, M II - - - 
47, M Ill - - + 
68, M II - - - 
54, F II - - + 
57, M II - - + 
57, M II - - - 
47, M II + - + 
44, M II - - - 
49, M II + - + 
68, M II - - + 
68, M Ill t t + 
60, M II - - - 
58, M II - - - 
54, M II - - t 
51, M Ill - - t 
39, M II - - t 
49, F II + - + 
67, F II - - - 
60, M II - - t 
54, M II - - t 
48, M II t - - 
46, M II - - t 
- - 66 
- t 77 
- - 69 
t 79 
- - 64 
+ - 65 
t 63 
- t 61 
- t 63 
t t 67 
t t 58 
t - 
- - 70 
t - 66 
t t 64 
- - 65 
t t 60 
t t 63 
t t 72 
- - 66 
t - 
t - 75 
EF = global ejection fraction; LAD = left anterior descending coronary 
artery: LC = left circumflexus; LM = left main coronary artery; NYHA = New 
York Heart Association functional class; PMI = previous myocardial infarction. 
of the vessels are detected automatically on the basis of 
the weighted sum of first and second derivative func- 
tions applied to the digitized brightness information. 
Calibration of the diameter data of the vessels in abso- 
lute values (mm) is achieved by using the contrast cath- 
eter as a scaling device. To this end, the contours of a 
user-defined portion of the optimally magnified cathe- 
ter [optimal magnification factor 2d2) are detected 
automatically and corrected for pincushion distortion 
caused by the image intensifier. From the contours, the 
vessel diameter functions [in absolute mm] are deter- 
mined by computing the shortest distances between 
the left and right contour positions. A representative 
analysis, with the detected contours and the diameter 
functions superimposed on the original video image, is 
shown in Figure 1. For nonobstructed coronary seg- 
ments, the mean arterial diameter of the analyzed seg- 
ment was computed. For obstructed segments, the 
minimal obstruction diameter was assessed. A total of 
103 coronary segments, including 17 stenotic segments, 
were selected from the study group angiograms for 
analysis. The fact that a limited number of stenotic 
lesions were analyzed in this study is due to: (11 selec- 
tion was based on the technical quality of the angio- 
grams, with clear views of the pre- and poststenotic 
segments: (2) orthogonal projections of the stenotic le- 
sions were required; and (3) only repeat angiography 
of the left coronary artery was performed. To ensure 
exact reproducibility of the sequential angiographic 
studies, the following measures were taken. First, as 
mentioned, the x-ray system was repositioned in the 
settings corresponding to the projections used during 
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TABLE II Coronary Hemodynamics Affer 20 mg of Nicorandil (n = 11) 
Control 
CSBF (mllmin) 115 f 12 
CVR (mm Hglmllmin) 1.0 f 0.1 
A0 0s content (ml %) 18.6 f 0.4 
CS O2 content (ml %) 9.6 f 0.3 
(AO-CS) O2 diff (ml %) 9.0 f 0.4 
MVOs (mllmin) 10.2 f 0.9 
Pressure-rate 9,976 f 705 
product (mm Hg X beatslmin) 
5 minutes 10 minutes 
122 f 12 123 f 14 
0.9 f 0.1 0.9 f 0.1 
16.6 f 0.4 16.5 f 0.4 
9.7 f 0.3 10.2 f 0.4’ 
8.9 i 0.4 8.4 f 0.5’ 
10.5 f 0.9 9.8 f 0.7 
9,937 f 835 9,281 f 592’ 
20 minutes 
113f 12 
0.9 f 0.1 
18.5 f 0.4 
10.3 f 0.4’ 
8.2 f 0.4’ 
9.0 f 0.8 
8,901 f 653’ 
30 minutes 
109 f 12 
0.9 l 0.1 
18.5 f 0.4 
10.2 f 0.4’ 
8.3 f 0.5’ 
6.8 i 0.9 
8,097 f 6223 
A0 = aorta; CSBF = coronary sinus blood flow; CVR = coronary vascular resistance; O2 = oxygen; diff = 
difference; MVOp = myocardial oxygen consumption, 
ikkIeS are eXpreSSed as mean f standard error of the mean. Only p values <0.65 (vs control) are reported: * p 
<0.05; + p <o.oi; t p <0.0005. 
the baseline angiography. Second, all study cine- 
frames to be analyzed were selected at end-diastole, to 
minimize any possible foreshortening effect. Third, 
the user-determined beginning and endpoints of the 
major coronary segments between side branches were 
standardized according to the definitions of the Amer- 
ican Heart Association.lg Finally, Polaroid@ pictures 
were taken of the video image with the detected con- 
tours superimposed, to ensure that the analyses were 
performed on the same coronary segment in the 2 con- 
secutive angiograms. 
Statistical analysis: Results are expressed as the 
mean f standard error of the mean. Analysis of vari- 
ance for repeated measurements was used and when 
overall significance was observed, multiple compari- 
FIGURE 1. Computer output of an analyzed coronary segment. The 
diameter function is superimposed on the video Image; the callbrat- 
ed diameter values In mm are plotted along the ordinate, and the 
centerllne posftlons from the proxlmal to the distal part along the 
abscissa. The reference position was defined proximal of the ste- 
notlc lesion, as Indicated In the diameter function by the shaded 
vertical bar. The central reference position Is marked in the artery 
by a straight line connecting the opposing contour slde. 
*O mm 
60 1 
I I , 
C 5 10 20 3Omin 
l p<.os l *P<.oos l ** p<.ooos l ***p<.oooos 
FIGURE 2. Systemic responses after admlnlstration of nlcorandll. C 
= control state; DAP = diastolic aortlc pressure; HR = heart rate; 
MAP = mean aortlc pressure; SAP = systolic aortlc pressure. 
sons were statistically assessed with Student t test. A p 
value of <O.O5 was considered significant. 
Results 
The systemic responses after 20 mg (group 1) and 40 
mg [group 2) of nicorandil are summarized in Figure 2. 
During spontaneous heart rate, nicorandil produced a 
significant decrease in aortic pressures, while heart 
rate remained unchanged. After 30 minutes, the mean 
changes were 25 mm Hg in group 1 (-1770, p <O.OOS) 
and 42 mm Hg (-2870, p <0.00005) in group 2 for the 
systolic aortic pressure, 7 mm Hg (-970, p <0.005) and 
12 mm Hg (-l5%, p <0.005) for the diastolic aortic 
pressure and 14 mm Hg (-13%, p <0.005) and 23 mm 
Hg (-2l%, p <0.0005) for the mean aortic pressure, 
respectively. 
Coronary hemodynamics: Coronary sinus blood 
flow did not change significantly in both groups. As the 
mean aortic pressure decreased significantly by 13% 
15m 
lOO- 
50- 
. Nicorsndil 20 mg 
. Nicormdll 40 mg 
l : 
Ln = 11) 
(n = 11) 
SAP 
MAP 
DAP 
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TABLE III Coronary Hemodynamics After 40 mg of Nicorandll (n = 11) 
Control 5 minutes 10 minutes 20 minutes 30 minutes 
CSBF (ml/min) 93f 12 94f 11 109 f 13 112 f 17 92 f 14 
CVR (mmHglml/min) 1.3 f 0.2 1.3 f 0.2 1.1 f 0.2 1.1 f 0.2 1.1 f 0.2 
A0 O2 content (ml %) 18.8 f 0.5 18.8 f 0.5 18.8 f 0.5 18.8 i 0.5 18.8 f 0.5 
CS O2 content (ml %) 9.5 f 0.5 10.2 f 0.4 10.6 f 0.6’ 11.1 f 0.5’ 11.1 f 0.57 
(AO-CS) 02 diff (ml %) 9.1 f 0.4 6.8 f 0.4 8.1 f 0.3’ 7.6 f 0.3t 7.6 f 0.37 
MV02 (mllmin) 9.0 f 1.1 8.2 f 1.0 a.7 f 1.1 8.5 f 1.3 7.0 f 1.1” 
Pressure-rate 10,866 f 741 10,824 f 907 10,395 f 952 9,444 f 908‘ 8,290 zk 7847 
product (mm Hg X beats/min) 
* p <0.05; t p <0.002; t p <0.0005. 
Abbreviations as in Table II. 
after 20 mg and 21% after 40 mg nicorandil, the calcu- 
lated coronary vascular resistance decreased but did 
not reach statistical significance. The mean arteriocor- 
onary sinus oxygen content difference decreased sig- 
nificantly in both groups by 8% (p <O.Ol) and by 16% 
(p <0.002], respectively. This significant decrease in 
arteriocoronary sinus oxygen difference, not associ- 
ated with an increase in coronary sinus blood flow, 
resulted in a decrease in myocardial oxygen consump- 
tion by 14% in group 1 and 22% in group 2 [Table II 
and III]. The decrease in the myocardial oxygen con- 
sumption is consistent with a significant decrease 
in the calculated pressure-rate product of 19% (p 
<0.0005) and 24% (p <0.002], respectively. 
Quantitative coronary angiograms: A total of 103 
coronary segments, including 17 stenotic segments, of 
the left coronary artery were analyzed. The mean ab- 
solute diameters (in mm) of the coronary segments, as 
measured during the 2 consecutive angiographies, are 
presented in Table IV and Figure 3. Thirty minutes 
after 20 mg of nicorandil, an increase of the mean 
diameter was observed in the proximal (+9%, p 
<0.003), midportion (-l-10%, p <0.08) and distal (+15%, 
p <O.OOOS] parts of the left anterior descending coro- 
nary artery. Corresponding values for the proximal 
and distal segments of the circumflex artery were 13% 
and 10% (p <0.003 for each). These significant changes 
in the mean coronary diameter were also observed to a 
similar extent after 40 mg of nicorandil. Among the 103 
coronary segments analyzed, 17 stenotic segments 
were measured (Table V). After nicorandil, an in- 
crease in the obstruction diameter was observed in all 
but 3 of the stenotic lesions (Figure 3). 
Discussion 
The general profile of response of nicorandil, a nic- 
otinamide nitrate (ester), is partly similar to that of the 
related substance, nitroglycerin. Both belong to a 
group of nitroesters, suggesting similar effects on the 
systemic and coronary hemodynamics. However, the 
differences between both drugs have been investi- 
gated.4J5J0 Nicorandil, unlike conventional nitrates, is 
probably slowly metabolized by the liver during pas- 
sage through the portal system, and therefore easily 
enters the general circulation, resulting in greater bio- 
availability after oral dosinge Kinoshita et alzl indicat- 
ed that nicorandil exerts beneficial effects on exercise 
capacity in patients with chronic stable angina pecto- 
ris 30 minutes after oral administration, Preliminary 
study has shown that plasma levels reach the highest 
value at that time.2? 
Chronotropic effect: In the route and doses used in 
the present study, the heart rate did not change signifi- 
cantly despite decreased aortic pressure. This finding 
is consistent with a number of anima11.3~ll~12~23~24 and 
clinicalz5J6 studies. However, in a systemic and coro- 
nary hemodynamic experimental study, Mizukami et 
al4 demonstrated a dose-related increase of heart rate 
due to a baroreflex tachycardia after an abrupt de- 
crease in arterial pressure after administration of nico- 
randil. These findings were essentially consistent with 
the results observed in a clinical study.6 In this study, 
all cardiac medications, including P-blockade agents, 
were discontinued 24 hours before catheterization. It 
could be speculated that some of the longer lasting 
effects of P-blockers may have partly contributed to 
TABLE IV Effect of Nicorandil on the Absolute Coronary Artery Diameter (mm) of All Analyzed Segments 
Nicorandil 20 mg Nicorandil 40 mg 
n Before After A p Value n Before After A p Value 
LAD-proximal 11 2.42 zk 0.19 2.64 f 0.21 f9% 0.003 11 2.53 zt 0.18 2.71 f. 0.20 l F7% 0.002 
LAD-mid 6 2.29 f 0.21 2.51 f 0.26 +lo% 0.08 9 1.94 & 0.12 2.16 zfz 0.11 +ll% 0.001 
LAD-distal 11 1.84 f 0.10 2.11 f 0.12 +150/o 0.0006 11 1.64 f 0.08 1.85 f 0.07 +13% 0.0002 
LC-proximal 11 2.44 f 0.16 2.75 f 0.15 +13% 0.002 11 2.56 f 0.18 2.85 f 0.18 +10% 0.00005 
LCdistal 11 2.09 f 0.12 2.29 f 0.15 +lo% 0.003 11 1.97 f 0.17 2.27 f 0.19 +159/o 0.00006 
Values are expressed as mean f standard error of the mean. 
LAD = left anterior descending coronary artery; LC = left circumflex. 
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TABLE V Effects of Nicorandii on the Stenotic Segments 
Nicorandil 20 mg (n = 7) Nicorandil 40 mg (n = 10) 
Before After A Before After A 
Extent obstruction (mm) 6.46 f 1.25 6.92 f 1.35 +7% 5.03 f 0.45 4.73 f 0.41 -6% 
Obstruction diameter (mm) 1.43 f 0.10 1.56 f 0.13 +100/ 1.29 f 0.14 1.44 f 0.16 +120/o* 
Obstruction area (mms) 1.66 f 0.45 2.20 f 0.60 +16% 1.34 f 0.27 1.76 f 0.36 +330/ l 
Diameter stenosis (%) 43.1 f 2.6 41.7 f 3.1 -3% 46.9 f 3.1 41.7 f 4.5 -15% l 
Area stenosis (%) 70.3 f 4.6 62.4 f 7.3 -11% 73.4 f 4.0 67.7 f 5.0 -6% 
Symmetry index 0.47 i 0.10 0.49 f 0.12 +40/ 0.56 f 0.10 0.56 f 0.10 0 
Reference diameter (mm) 2.50 f 0.18 2.83 & 0.16 +130/ot 2.22 f 0.11 2.39 f 0.12 +8%’ 
Reference area (mm*) 5.09 f 0.75 6.45 f 0.75 +279/o+ 3.95 f 0.39 4.57 f 0.43 +160/o’ 
Values are expressed as mean f standard error of the mean. 
Only p values of <0.05 are reported: l p <0.03; t p <0.005. 
the effect on heart rate and to the observed increases 
in coronary artery dimensions, P-blockers used alone 
produce a reduction in myocardial oxygen consump- 
tion, increase coronary vascular resistance and reduce 
coronary sinus blood flow,27J8 which may have in- 
creased the sensitivity to the vasodilator effects of ni- 
corandil. However, the resting heart rates of our study 
population suggest minimal P-blockade effect at the 
initiation of the study. Thus, we conclude that the ob- 
served increases in coronary dimensions are indeed 
the result of the administration of nicorandil. 
Effect on coronary hemodynamics: Verdouw et 
all4 reported that after nicorandil, although left ven- 
tricular transmural blood flow was not affected, its 
distribution over the myocardium changed in favor of 
the subepicardial layers. Flow to the subendocardium 
decreased by Xl%, whereas that to the subepicardium 
increased by 6570, which is in agreement with the 
observation of Preuss et de15 As aresult the endocardi- 
al-epicardial blood flow ratio decreases. However, if 
the decrease in aortic pressure after nicorandil is pre- 
vented by use of a cuff around the descending thoracic 
I h I 0 
-10 - 
0 
-20 
mid dlside prox dlatsle 
,. -uD6’y& g; LAD LAD LCX LCX 
0b*40tioll 
diameter 
FIGURE 3. reti, percentuai changes (A%) in coronary artery dlam- 
eter in the proximal (prox), mldportlon (mld) and dlstai parts of the 
left anterior descending (LAD), and proximal and distal parts of 
circumflex (LCX) coronary artery. The Increase in the coronary 
artery diameter was more pronounced in the dlstai segments when 
compared to the proximal segments (‘p <0.03 vs LAD prox). RIgM, 
percentuai changes (A%) In the obstruction diameter. 
aorta, collaterai blood flow to the subendocardial lay- 
ers of an ischemic area increases to a similar extent as 
that to the subepicardial layers.aJO Using the intracoro- 
nary route of administration, in order to minimize sys- 
temic responses, nicorandil selectively increased epi- 
cardial blood flow suggesting a preferential suscepti- 
bility of the epicardium to the vasodilator action of 
nicorandil.14 
The coronary sinus blood flow, as measured by 
thermodilution in this study, is a mixture of flow com- 
ing from the region supplied by normal and stenotic 
coronary artery, and the results should be interpreted 
with this in mind. In the doses used in this study, coro- 
nary sinus blood flow remained unchanged, despite 
the nicorandil-induced hypotension. Therefore, coro- 
nary vasodilation must have taken place, although the 
decrease in coronary vascular resistance did not reach 
statistical significance. There was a slight decrease in 
myocardial oxygen consumption (-14% and -2.~0, 
respectively) reflected by a significant decrease in 
arteriocoronary sinus oxygen difference (-8% and 
-16%) respectively, p <O.Ol), as coronary sinus oxygen 
content increased significantly. This was consistent 
with a significant decrease in the calculated pressure- 
rate product. The finding is in agreement with an ani- 
mal experimental study.14 
Quantitative coronary angiography: When per- 
forming pharmacologic interventions during coronary 
angiography, 2 different approaches may be used: ei- 
ther repeated angiography in the same single view 
without altering the x-ray setting or use of multiple 
angiographic views. In the first case, if the coronary 
segment is nonaxisymmetric, induced vasodilation 
may accentuate the asymmetry of the lumen by prefer- 
entially relaxing the nonatherosclerotic part of the ar- 
terial wall. Consequently, the use of a single angio- 
graphic view will be misleading. It therefore follows 
that the effects of a vasodilatory agent will be better 
quantified if multiple projections are obtained. This 
will increase the accuracy of diameter measurements 
and will better reflect the true luminal cross-sectional 
area. 
Our results demonstrate that nicorandil causes a 
significant vasodilatation in the normal coronary seg- 
ments, as well as in the majority of the stenotic seg- 
ments. In fact, the percentage of increase in the diame- 
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ter of the nonobstructed segments was more pro- 
nounced in the distal segments when compared with 
the proximal segments as shown in Figure 3. This more 
pronounced istal vasodilation was also observed with 
other vasodilatory agentszg 
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